



Immune Design
 Investor Relations Department
 Immune Design Corp. Attn:
 Accounts Payab
 601 Gateway Blvd. Suite 250
 South San Francisco, CA 94080
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

| | |
|---------------|--|
| Last Trade: | 3.65 |
| Trade Time: | 11:48 AM ET Dec 18, 2017 |
| Change: | 0.05 ↑ (+1.250%) |
| Day Range | 3.50 - 3.75 |
| 52-Week Range | 3.50 - 13.05 |
| Volume | 221,820 |

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 10, 2017
[Combination of G100 with KEYTRUDA \(pembrolizumab\) Triggers Robust Systemic Responses in Follicular NHL Patients](#)
- Nov 13, 2017
[Immune Design to Present at Jefferies 2017 London Healthcare Conference](#)
- Nov 7, 2017
[Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates](#)
- Nov 1, 2017
[Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Oct 27, 2017
[Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 7, 2017
[Annual Report \(10-K\)](#)
- Apr 26, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 4, 2017
[Quarterly Report \(10-Q\)](#)